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Lysophosphatidic acid (LPA) is an extracellular lipidmediator involved inmany physiological functions that signals through six known
G-protein-coupled receptors (LPA1–LPA6). A wide range of LPA effects have been identified in the CNS, including neural progenitor cell
physiology, astrocyte and microglia activation, neuronal cell death, axonal retraction, and development of neuropathic pain. However,
little is known about the involvement of LPA in CNS pathologies. Herein, we demonstrate for the first time that LPA signaling via LPA1
contributes to secondary damage after spinal cord injury. LPA levels increase in the contused spinal cord parenchyma during the first
14 d. To model this potential contribution of LPA in the spinal cord, we injected LPA into the normal spinal cord, revealing that LPA
induces microglia/macrophage activation and demyelination. Use of a selective LPA1 antagonist or mice lacking LPA1 linked receptor-
mediated signaling to demyelination, which was in part mediated by microglia. Finally, we demonstrate that selective blockade of LPA1
after spinal cord injury results in reduced demyelination and improvement in locomotor recovery. Overall, these results support LPA–
LPA1 signaling as a novel pathway that contributes to secondary damage after spinal cord contusion in mice and suggest that LPA1
antagonismmight be useful for the treatment of acute spinal cord injury.
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Introduction
Spinal cord injury (SCI) causes functional deficits produced by the
loss of axons and neurons and contributes to the death of oligoden-
drocytes and the limited ability of the CNS to regenerate axons
(Rowland et al., 2008; David et al., 2012a). The pathophysiology of
SCI involves two stagesof tissuedegenerationknownasprimaryand
secondary injury. Primary injury results from the direct mechanical
trauma to the spinal cord, which is followed by secondary injury,
consisting of a wave of tissue degeneration that occurs over a period
of several weeks, and is associated with inflammation and other
mechanisms triggered by injury (David et al., 2012a,b; Popovich,
2014). Secondary injury is thought to contribute importantly to the
functional deficits seen after SCI andmay be preventable. Repairing
the damaged spinal cord is still a clinical challenge. Neuroprotective
strategies aimedatpreventingdamage arising fromsecondary injury
processes provide some hope for tissue sparing and improved func-
tional outcome. However, there is currently no effective clinical
treatment for SCI. Hence, there is a need to identify factors that are
involved in triggering secondary damage in SCI and to develop drug
interventions to limit damage and improve functional deficits.
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Significance Statement
This study reveals that LPA signaling via LPA receptor type 1 activation causes demyelination and functional deficits after spinal
cord injury.
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Lysophosphatidic acid (LPA; 1-acyl-sn-glycerol 3-phosphate)
is a bioactive lipid that has a wide variety of biological activities,
including cellular proliferation, prevention of apoptosis, cell mi-
gration, cytokine and chemokine secretion, platelet aggregation,
smooth muscle contraction, and neurite retraction (Bot et al.,
2010; Choi et al., 2010; Choi and Chun, 2013; Yung et al., 2014).
LPA exerts this wide variety of effects by binding to specific
G-protein-coupled receptors, such as LPA receptors (LPARs)
LPA1–LPA3, which belong to the endothelial differentiation gene
family, and the genetically more distant LPA4–LPA6, which be-
long to the P2Ypurinergic receptor family (Choi et al., 2010; Choi
and Chun, 2013; Kihara et al., 2014). These receptors differ in
their ability to alter downstream signaling pathways, including
intracellular Rho levels, mobilize Ca2, contribute to phospho-
inositol turnover, and to activate intracellular kinases, such as
MAPK and ERK (Choi et al., 2010; Choi and Chun, 2013).
In vivo studies demonstrate that LPA is involved in the etiol-
ogy of fetal hydrocephalus (Yung et al., 2011), fetal hypoxic brain
damage (Herr et al., 2011), and the development of neuropathic
pain after sciatic nerve injury and cerebral ischemia (Inoue et al.,
2004; Frisca et al., 2012; Lin et al., 2012). Because of the wide
variety of LPAR subtypes, it is likely that LPAmay exert helpful or
harmful effects in the CNS depending on the receptors it signals
through. Thus, there is a need to know which LPARs contribute
to neurodegeneration and/or neuroprotection. Here we show
that LPA levels increase in the spinal cord parenchyma after con-
tusion injury. We provide evidence suggesting that LPA leads to
demyelination via activation of microglia LPA1. Moreover, we
demonstrate that selective blockade of LPA1 after SCI reduces
functional deficits and demyelination, altogether revealing im-
portant contributions of LPA–LPA1 signaling in secondary dam-
age after SCI.
Materials andMethods
Surgical procedure
All surgical procedures were approved by the Autonomous University of
Barcelona Animal Care Committee and followed the guidelines of the
European Commission on Animal Care. Adult (8–10 weeks old) female
C57BL/6 mice (Charles River), LPA1-deficient mice (maLPA1-null;
Estivill-Torru´s et al., 2008), orwild-type littermates (C57BL/6J 129X1/
SvJ background) were anesthetized with ketamine (90 mg/kg, i.m.) and
xylazine (10 mg/kg, i.m.). After performing a laminectomy at the 11th
thoracic vertebrae, the exposed spinal cord was either injected intraspi-
nally or contused.
Intraspinal injections were performed using a glass needle (30 m
internal diameter; Eppendorf) coupled to a 10mlHamilton syringe (cat-
alog #701; Hamilton). One microliter of saline, saline containing 5 nmol
of LPA (18:1 LPA; Sigma-Aldrich), or 5 nmol of LPA plus the selective
LPA1 antagonist AM095 sodium, {4’-[3-methyl-4-((R)-1-phenyl-etho-
xycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetate 0.22 nmol;
kindly provided by Bristol-Myers Squibb; Swaney et al., 2011) was in-
jected into the dorsal column of the uninjured spinal cord. Injections
were made at a perfusion speed of 2 l/min controlled by an automatic
injector (KDS 310 Plus; KD Scientific), and the tip of the needle was
maintained inside the cord tissue 3 min after each injection to avoid
liquid reflux.
SCIs were performed using the InfiniteHorizon Impactor device (Pre-
cision Scientific), using a force of 50 kdyn and tissue displacement rang-
ing from 400 to 600m(Klopstein et al., 2012).When indicated, AM095
or saline was administered orally at a dose of 30 mg/kg. Treatment was
initiated 1 h after SCI and then given every 12 h for 1 week.
Functional assessment
Locomotor recovery was evaluated at 1, 3, 5, 7, 10, 14, 21, and 28 d
post-injury (dpi) in an open-field test using the nine-point BassoMouse
Scale (BMS; Basso et al., 2006), which was developed specifically for
locomotor testing after contusion injuries in mice. The BMS analysis of
hindlimbmovements and coordination was performed by two indepen-
dent assessors who were blinded to the experimental groups and the
consensus score taken. In addition, at the end of the follow-up (28 dpi),
the highest locomotion speed of the mice was evaluated on a belt of a
motorized treadmill. Briefly, each mouse was allowed to explore the
treadmill compartment, with themotor speed set to zero, for 5min. Then
speed was gradually increased from 0 up to 35 cm/s, and the maximum
speed at which each mouse was to perform for at least 5 s was recorded.
Motor-evoked potentials
At day 28, electrophysiological tests were used to evaluate spared motor
central pathways after SCI. Motor-evoked potentials (MEPs) were re-
corded from the gastrocnemius muscle (GM) with microneedle elec-
trodes, in response to transcranial electrical stimulation of the motor
cortex by single rectangular pulses of 0.1 ms duration. Pulses were deliv-
ered through needle electrodes inserted subcutaneously, with the cath-
ode over the skull overlying the sensorimotor cortex and the anode at the
nose (García-Alías et al., 2003). Compoundmuscle action potential from
GMmuscle was recorded for internal control of normal peripheral con-
duction. In this case, the sciatic nerve was stimulated percutaneously by
means of single pulses of 0.02 ms duration (Grass S88; Grass Instru-
ments) delivered through a pair of needle electrodes placed at the sciatic
notch. All potentials were amplified and displayed on a digital oscillo-
scope (Tektronix 450S).
Cell cultures
Mouse oligodendrocyte cultures. Primary oligodendrocyte progenitor cells
(OPCs) were isolated frommouse cerebral cortex at postnatal day 2 (P2)
to P4 as described previously (O’Meara et al., 2011). Briefly, after re-
moval of the meninges, cortical tissue was minced using a P1000 pipette
tip and dissociated by incubating in a solution of 1.54 mg/ml papain
(Worthington Biochemical), 400g/ml L-cysteine (Sigma), and 1mg/ml
DNase I (Roche) inMEM (Gibco) for 20min at 37°C.Mixed glial culture
media [MGCM; 10% inactivated and filtered fetal bovine serum (FBS;
Sigma), 0.33% penicillin–streptomycin (P/S; Sigma), and 1% Glutamax
100 (Gibco) in DMEM (Gibco)] was added to stop papain and DNase
I activity. Cells were plated into T25 tissue culture flasks coated with 10
g/ml poly-D-lysine for 1 h at 37°C and cultured at 37°C in an humidified
incubator with 5% CO2 supplementation. Three hours after plating, the
floating cells were discarded by replacing the medium. Two thirds of the
MGCM was replaced every 3 d with new MGCM supplemented with 5
g/ml insulin (Seralab).Nine days later, OPCswere harvested by shaking
at 37°C at 220 rpm overnight. The collected cells were plated into 10
g/ml poly-D-lysine-coated coverslips with DMEM (Gibco) supple-
mented with 1% Glutamax 100, 2% B27 (Gibco), 0.5% FBS, 50 pg/ml
recombinant mouse ciliary neurotrophic factor (BioTrend), and 1% OL
supplement (10 l/ml N-2 supplement 100 (Gibco), 10 mg/ml bovine
serum albumin (Sigma), and 40 g/ml 3,3,5-triiodo-L-thyronine
(Sigma). OPC maturation in oligodendrocytes was achieved after 7 d in
vitro.
Mouse microglia cultures. Primary microglial cells were isolated from
P4 mouse cerebral cortex as described previously (Saura et al., 2003).
Tissue dissociation and cell isolation was performed as described in OPC
culture. Mixed glial cultures were prepared into T25 tissue culture flasks
without any coating. Cells were seeded at a density of 300,000 cells/ml in
DMEM/F-12 (Gibco) with 10% FBS and 5% P/S and cultured at 37°C in
a humidified incubator with 5% CO2 supplementation. Medium was
replaced every 4–5 d, and confluence was achieved after 10–12 d. At this
point,mixed cultures were incubatedwith 0.25% trypsin–EDTA (Gibco)
diluted 1:4 in DMEM/F-12 for 30 min at 37°C. This trypsinization re-
sulted in the detachment of the upper layer of cells in one piece, and the
remaining adherent microglial cells were cultured for 24 h before stim-
ulation. Microglial cells were stimulated with LPA (1 M) or LPA plus
AM095 (12.5 M) or 0.025% DMSO (vehicle for AM095) as control for
24 h. Afterward, cells were washed to remove the LPA from themedium,
and microglia were then incubated with oligodendrocyte conditioned
media for 24 h and then used for cytotoxicity assays in oligodendrocyte
cell cultures.
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Assessment of oligodendrocyte cell death
Oligodendrocytes were stimulated with LPA (0.01, 0.1, or 1 M), LPA
plus AM095 (12.5 M), and DMSO (0.025%) as control, or with
conditioned media of microglia harvested from C57BL/6 mice,
maLPA1 null mice, or wild-type littermates, stimulated with DMSO,
LPA, (1 M), or LPA (1 M) plus AM095 (12.5 M) for 24 h. After-
ward, coverslips were fixed in 4% paraformaldehyde for 20 min,
washed in PBS, and incubated overnight with rat anti-MBP (1:300;
Abcam), mouse anti-A2B5–Alexa Fluor 488 (1:100; Millipore), and
rabbit anti-NG2 (1:100; Millipore) in 0.3% Triton X-100/PBS with
5% fetal calf serum at 4°C. After several washes in PBS, coverslips were
incubated for 1 h at room temperature (RT) with anti-rat or anti-
rabbit Alexa Fluor 594-conjugated antibody (1:500; Invitrogen) and
DAPI (Sigma), and the total number of oligodendrocytes (MBP
cells) or oligodendrocytes precursor cells (A2B5 and NG2) were
counted under fluorescence microscope (Olympus BX51). Four in-
dependent replicates were done for each of the experiments.
Histology
At 4 d after intraspinal injection and 28 d after spinal cord contusion,
mice were perfusedwith 4%paraformaldehyde in 0.1 M phosphate buffer
(PB). A 10 mm length of spinal cord containing the injection or the
contusion site centered was harvested, postfixed with 4% paraformalde-
hyde in 0.1 M PB for 1 h, and cryoprotected with 30% sucrose in 0.1 M PB
at 4°C for a minimum of 48 h. The samples were fast-frozen at60°C in
cryoembedding compound (Tissue-Tek OCT; Sakura) and cut on a cry-
ostat (Leica). Ten series of 10-m-thick transversal sections were picked
up on glass slides, so adjacent sections on the same slide were 100 m
apart. For demyelination and myelin sparing analyses, sections were
stained with Luxol fast blue (LFB; Sigma) or fluoromyelin (Invitrogen).
After graded dehydration, sectionswere placed in a 1mg/ml LFB solution
in 95% ethanol and 0.05% acetic acid overnight at 37°C. Sections were
then washed in 95% ethanol and distilled water before being placed in a
solution of 0.5 mg/ml Li2CO3 in distilled water for 1 min at RT. After
washes in distilled water, sections were dehydrated andmounted in DPX
mounting media (Sigma). For immunofluorescence staining, sections
were rehydrated in PBS and blocked with 5% FBS in PBS with Tween 20
(PBST) for 1 h at RT. The sections were then incubated overnight at 4°C
with primary antibodies against NeuN (for neurons; 1:200; Millipore),
neurofilament-200 (NF-200; for axons; 1:1000; Millipore), GFAP (for
astrocytes; 1:500; Invitrogen), ionized calcium-binding adaptermolecule
1 (Iba1; for macrophage/microglia; 1:400; Abcam), and MBP (for my-
elin; 1:100; Abcam). After several washes in PBST, sections were incu-
bated for 1 h at RT with the appropriate Alexa Fluor 594 or 488-
conjugated secondary antibodies (1:200; Invitrogen) and then
coverslipped in Mowiol mounting media containing DAPI (1 g/ml;
Sigma). Tissue sections were viewed with anOlympus BX51microscope,
and images were captured with an Olympus DP50 digital camera at-
tached to it and using the CellAˆ Image acquisition software.
The epicenter of the injection or contusion injury impact was deter-
mined for eachmouse spinal cord by localizing the tissue sectionwith the
greatest demyelination. The NIH ImageJ software was used to quantify
the histological parameters. For experiments injecting LPA, demyelina-
tion was measured by delineating LFB nonstained white matter in the
dorsal column, whereas microglia activation was assessed by calculating
the percentage of Iba1 immunoreactivity area within a 0.025 mm2 box
placed within the dorsal column. For SCI experiments, myelin sparing
after SCI was calculated by delineating the spared fluoromyelin-stained
tissue, whereas neuronal survival was assessed by counting the number of
NeuN cells in the ventral horns. Moreover, axonal and demyelination
in the dorsal columnwas assessed by counting theNF structures as well
as fibers double stained for NF and MBP at the lesion epicenter.
Electron microscopy
Four and 21 d after intraspinal injection of LPA or saline, mice were
perfused with 0.5% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M
PB, pH 7.4. Five-millimeter-thick cross-sections of the spinal cord con-
taining the injection site were left in the same fixative for several days,
followed by postfixation in 2% osmium tetroxide for 2 h at RT and then
processed for embedding in Epon. One-millimeter-thick cross-sections
of the spinal cord were stained with 1% toluidine blue for light micros-
copy. Then, sections were cut at 90 nm, stained with lead citrate, and
viewed with a Philips CM 10 electron microscope.
Flow cytometry
Immune cells from the injured spinal cord were analyzed by flow cytom-
etry at 7 dpi, as described previously (Klopstein et al., 2012). Briefly,
spinal cords were cut in little pieces and passed through a cell strainer of
70 m (Falcon; BD Bioscience Discovery Labware), and the cell suspen-
sion was centrifuged twice at 300  g for 10 min at 4°C. Samples were
divided, and cells alone and isotype-matched control samples were gen-
erated to control for nonspecific binding of antibodies and for autofluo-
rescence. Isotype control antibodies were purchased from eBioscience
and included phycoerythrin–cyanine 7 (PE–Cy7)-labeled rat IgG2b,
adenomatous polyposis coli (APC)-labeled rat IgG2b, peridinin
chlorophyll-a protein cyanine 5.5 (PerCP–Cy5.5)-conjugated rat IgG2b,
and fluorescein isothiocyanate-conjugated rat IgG2b and IgG2M. The
following antibodies were also purchased from eBioscience: CD45–
PerCP–Cy5.5, CD11b–PE–Cy7, and F4/80–APC. After 30 min of incu-
bation with combinations of antibodies at 4°C, the samples were washed
and fixed in 1% paraformaldehyde. Microglial cells were identified
as CD45 low and CD11b cells, whereas myeloid cells were identified as
CD45high and CD11b cells (Stirling and Yong, 2008). Macrophages
were identified frommyeloid cells based on F4/80 expression (CD45high,
CD11b, F4/80). At least 3000 CD45 cells were analyzed per spinal
cord sample using FlowJo software on a FACSCanto flow cytometer (BD
Biosciences). Four contused mice treated with saline or AM095 were
used in this experiment.
Isolation of microglia from CNS tissue
Briefly, spinal cord and brain from adult C57BL/6mice (8–10weeks old)
were removed and digested enzymatically with 0.2% collagenase B
(Roche Diagnostics) and 0.2% trypsin–EDTA at 37°C for 30 min and
then passed through a cell strainer of 40 m (Falcon; BD Bioscience
Discovery Labware). Cell suspensionwas centrifuged twice at 300 g for
10min at 4°C, andmicroglial cells were first isolated bymagnetic sorting
using a CD11b antibody (Miltenyi Biotec) and then stained with PerCP–
Cy5.5-conjugated CD45 and PE–Cy7-conjugated CD11b antibodies for
additional purification on a cell sorter (FACSARIA III; BD Bioscience).
Microglia cells were assessed on a flow cytometer (FACSCalibur; BD
Biosciences), and only populations presenting 90% purity were used
for gene expression analysis.
RNA isolation, reverse transcription, and real-time PCR
Mice were perfused with sterile saline, and a 5-mm-length of unin-
jured spinal cord was removed. Tissue was homogenized with QIAzol
lysis reagent (Qiagen) and RNA extracted using the RNeasy Lipid
Tissue kit (Qiagen), according to the protocol of the manufacturer.
RNA was treated with DNaseI (Qiagen) to eliminate genomic DNA
contamination. mRNA from cultured and in vivo sorted microglia
was extracted using the RNeasy Micro kit following the guidelines of
the manufacturer. One and 0.5 g of RNA obtained from tissue or
microglia, respectively, was primed with random hexamers (Pro-
mega) and reverse transcribed using the Omniscript RT kit (Qiagen).
RNase inhibitor (Roche) was added (1 U/l final concentration) to
avoid RNA degradation. Primer sequences are specified in Table 1.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a
housekeeping gene. The amount of cDNA was calculated based on the
Table 1. Real-time PCR primer sequences
Gene Forward primer (5-3) Reverse primer (5-3)
LPA1 TGTCCTGGCCTATGAGAAGTTCT TTGTCGCGGTAGGAGTAGATGA
LPA2 CTCACTGGTCAATGCAGTGGTATAT GAAGGCGGCGGAAGGT
LPA3 GGGACGTTCTTCTGCCTCTTTA GAAAGTGGAACTTCCGGTTTGT
LPA4 GATGGAGTCGCTGTTTAAGACTGA TGTTTGATCACTAACTTCCTCTTGGATA
LPA5 CCGTACATGTTCATCTGGAAGAT CAGACTAATTTCTCTTCCCACCT
LPA6 ACTGCTGCTTTGACCCTATTG AAGGTCTGTAGGTTGTGTTGG
GAPDH TCAACAGCAACTCCCACTCTTCCA ACCCTGTTGCTGTAGCCGTATTCA
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threshold cycle (CT) value and was standardized by the amount of
housekeeping gene using the 2CT method (Livak and Schmittgen,
2001).
Mass spectrometry analysis of LPA in the spinal cord
Mice were perfused with sterile saline, and a 5-mm-length of unin-
jured or injured spinal cord centered at the impact site was harvested
at 6 h and 1, 3, 7, and 14 dpi. Samples were homogenized in 0.01%w/v
butylated hydroxytoluene in PBS. After centrifugation at 15,000  g
for 20 min at 4°C, supernatants were processed for protein concen-
tration determination using the BCA protein assay (Pierce).
The volume corresponding to 300 g of protein was taken of every
sample. Two hundred picomoles of 1-O-dodecanoyl-2-dodecanoyl
phosphatidic acid was added as internal standard and water up to 100l.
Samples were acidified with 500 l of H2O/HCl at 19:1, and LPA species
were extracted with 500 l of water-saturated butanol twice. Organic
phase was recollected, evaporated until dryness, and resuspended in 100
l of CHCl3. Fifty microliters of this extract were injected in a high-
performance liquid chromatograph equipped with a Hitachi LaChrom
Elite L-2130 binary pump and a Hitachi Autosampler L-2200 (Merck)
coupled to a Bruker esquire6000 ion-trap mass spectrometer (Bruker
Daltonics). The column was a Supelcosil LC-Si 3 m 150  3 mm col-
umn (Sigma-Aldrich) protected with a Supelguard LC-Si 20  3 mm
guard cartridge (Sigma-Aldrich). Mobile phase was a gradient of solvent
A (chloroform/methanol/32% ammonium hydroxide at 75:24.5:0.5
v/v/v) and solvent B (chloroform/methanol/water/32% ammonium hy-
droxide at 55:39:5.5:0.5 v/v/v/v). The gradient was started at 100% sol-
vent A; it was decreased linearly to 50% solvent A in 2 min, maintained
for 4 min, to 0% solvent A in 6 min, and maintained there for an addi-
tional 18min. The flow rate was 0.5 ml/min in the chromatographic step
and 0.2 ml/min entered into the electrospray interface of the mass spec-
trometer. Nebulizer gas was set to 30 lb per square inch, dry gas to 8
l/min, and dry temperature to 365°C. LPA species were detected in neg-
ative ion mode with the capillary current set at 3500 V as deprotonated
molecular ions [M-H].
Statistical analysis
All analyses were conducted through IBM SPSS Statistics version 19.
Two-tailed Student’s t test was used for the single comparison between
two groups. Maximal speed on a treadmill was analyzed using the
Mantel–Cox test. Functional follow-up for BMS score and subscore, as
well as histological analysis ofmyelin andneuronal sparingwere analyzed
using two-way repeated-measures (RM) ANOVA. The rest of the data
were analyzed using one-way or two-way ANOVA depending on the
appropriate design. Post hoc comparisons were performed only when a
main effect showed statistical significance. p values for multiple compar-
isons were adjusted using Bonferroni’s correction. Results are expressed
as mean and SE. Differences were considered significant at p 0.05.
Results
LPA levels are increased in the injured mouse spinal cord
We first assessed whether LPA levels increased in the spinal cord
after contusion injury. Usingmass spectrometry, we detected the
presence of three LPAmolecular variants (18:1, 18:0, and 20:1) in
the uninjured spinal cord (Table 2). After contusion injury, these
three LPA species were elevated significantly at all time points
analyzed (one-way ANOVA; post hoc Bonferroni’s test, p 0.01;
n	 4 per time point). Moreover, additional LPA variants (16:0,
20:4, 22:6, and 22:4) were also detected in the contused spinal
cord (Table 2). Quantification of the different LPA species re-
vealed that the total level of LPA increased very rapidly in the
injured spinal cord (Fig. 1), being approximately fivefold higher
at 6 h, rising to 
10-fold at day 3, and the remaining approxi-
mately eightfold increased from 7 to 14 dpi compared with intact
spinal cord (one-way ANOVA; post hoc Bonferroni’s test, p 
0.01; n	 4 per time point). These results demonstrate that LPA
levels increase in the spinal cord after contusion injury.
Exogenous LPA exposure leads to demyelination
To assess the potential contribution of increased levels of LPA in
the spinal cord parenchyma, we injected 1l of saline containing
5 nmol of LPA into the dorsal column of uninjured spinal cord or
saline alone as a control group. The LPA variant used in these
experiments was the 18:1 oleoyl LPA, because our mass spec-
trometry results revealed that this LPA species was the most
abundant in the contused spinal cord.Microglia/macrophage ac-
tivation in the spinal cord parenchymawas assessed bymeasuring
the presence of reactive Iba1 cells, 4 d after injection.Microglia/
macrophage activation was restricted to the injection area in
saline-injected mice, probably because of the mechanical injury
caused by the needle insertion (Fig. 2A–C). By comparison, spi-
nal cord sections from mice injected with LPA showed a marked
activation ofmicroglia/macrophages 4 d after injection (Fig. 2D).
The presence of these inflammatory cells was not limited to the
injection site but were also distributed within the whole dorsal
columns (Fig. 2D). In addition, the immunoreactivity for Iba1
Figure 1. Increased LPA levels in the contused spinal cord. Mass spectrometry analyses of
LPA in spinal cord tissue fromuninjuredand contused spinal cord at 6hand1, 3, 7, and14dafter
SCI (n	 4 time point). *p 0.05. Error bars indicate SEM.
Table 2. Quantification of the different LPA species in SCI
LPA species 16:0 18:1 18:0 20:4 20:1 22:6 22:4 22:1
Intact 0 33.5 7.1 34.6 3.2 0 7.1 1.5 0 0 0
6 h 7.7 0.3* 166.4 9.0* 79.7 4.4* 10.5 0.9* 77.8 5.8* 55.0 4.5* 15.1 0.7* 0.4 0.1
1 d 7.4 0.9* 167.8 18.6* 80.5 8.3* 13.1 1.8* 94.0 8.4* 60.3 6.1* 14.9 1.9* 0.5 0.1
3 d 13.4 1.0* 290.5 21.2* 143.3 10.5* 20.2 1.1* 144.0 12.9* 85.0 6.2* 25.5 1.7* 0.7 0.0
7 d 12.9 0.8* 255.4 7.1* 125.4 4.1* 21.9 0.7* 119.8 6.1* 73.4 2.3* 22.3 0.5* 0.7 0.0
14 d 0 307.7 35.7* 125.1 8.2* 25.7 2.0* 52.1 8.2* 82.0 7.6* 13.6 2.3* 0
*p 0.01 versus intact spinal cord.
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cells was also increased in rostral and caudal areas from the injec-
tion site in LPA-injected compared with saline-injected mice
(Fig. 2; two-way RM-ANOVA; post hoc Bonferroni’s test, p 
0.05; n 	 4 per group). Mild activation of astrocytes was also
observed but were only restricted to areas close to the LPA injec-
tion (data not shown), indicating that LPA activates both micro-
glia and astrocytes but has a greater preference for microglia.
We then assessed whether activation of microglia/macro-
phages triggered by LPA led to demyelination. At 4 dpi, LFB
staining revealed the presence of a small demyelinating lesion in
the dorsal column of saline-injected spinal cords (Fig. 3), which
was restricted to the area of the needle insertion (Fig. 3B).We also
observed a demyelinating lesion in the spinal cords injected with
LPA (Fig. 3D). The area of this lesion was significantly increased
in LPA-injected compared with PBS-injected mice at the injec-
tion epicenter and in adjacent areas (Fig. 3A–E; two-way RM-
ANOVA; post hoc Bonferroni’s test, p 0.05; n	 4 per group).
To assess whether demyelination induced by LPA was caused by
axonal or myelin damage, we double stained spinal cord sections
with fluoromyelin and NF. Double immunofluorescence re-
vealed the presence of NF structures within the demyelinating
lesion (Fig. 3F), suggesting that LPA led to demyelination. To
further confirm these observations, we used electronmicroscopy
(Fig. 3G–J). This technique confirmed the presence of fibers with
degenerating myelin (Fig. 3H, I) and naked axons (Fig. 3J)
within the demyelinating lesion. Therefore, these results indicate
that the increased levels of LPA in the spinal cord leads to neuro-
inflammation and demyelination.
Exogenous LPA exposure mediates demyelination via LPA1
Because LPA signals through six different LPARs, we studied
which LPARs were expressed constitutively in the normal spinal
cord. Real-time PCR analysis revealed that all six LPARs are ex-
pressed constitutively in the uninjured spinal cord, with LPA1
being themost highly expressed (Fig. 4; n	 4 per time point). To
assess whether the demyelination triggered by intraspinal injec-
tion of LPA was mediated via LPA1, we injected LPA together
with AM095, a selective LPA1 antagonist (Swaney et al., 2011),
into the intact spinal cord. Histological analysis revealed that 4 d
after LPA administration, the demyelinating lesion was reduced
substantiallywhenLPA1was blocked (Fig. 5A–C).Quantification
of the demyelinated areas revealed that mice treated with AM095
showed reduced myelin loss at the injection site and in the adja-
cent sections corresponding to 600 m rostral and caudal to the
epicenter (two-way ANOVA; post hoc Bonferroni’s test, p 0.05;
n	 4 per group). Spinal cord tissue sections fromLPA1 nullmice
(maLPA1 variant) also displayed smaller demyelinating lesions
(Fig. 5D–F) after intraspinal injection of LPA, further implicat-
ing LPA1 signaling in LPA-induced demyelination.
Because LPA1 is expressed in mature oligodendrocytes
(Weiner et al., 1998), we assessed whether LPA-induced demy-
elination was attributable to a toxic effect of LPA on oligoden-
drocytes. Cell culture work indicated that LPA treatment led to a
mild reduction in the viability of oligodendrocytes (
20%) at
concentrations of 1M (Fig. 6A; n	 4 per group). However, LPA
did not have an effect on oligodendrocyte precursor cell survival
(Fig. 6B). Administration of AM095 failed to rescue cultured
oligodendrocytes from cell death, suggesting that the LPA1 sig-
naling does not mediate a direct cytotoxic effect in cultured oli-
godendrocytes (Fig. 6C; n	 4 per group), albeit with the caveat
that these cells only approximate what occurs in vivo. Because
LPA also triggers microglia activation when injected into the spi-
nal cord and activated microglial cells were associated with areas
of demyelination (Fig. 6D), we also assessed whether microglial
LPA1 was responsible for the LPA-induced demyelination. In
agreement with previous work (Mo¨ller et al., 2001; Tham et al.,
2003) real-time PCR analysis identified LPA1 gene expression in
cultured microglia (Fig. 6F; n	 4). Moreover, microglial cells in
vivo have constitutive expression of LPA1, showing similar levels
of LPA1 relative to cultured microglia (Fig. 6E,F; n 	 4). Inter-
estingly, we observed that conditioned medium of primary mi-
croglial cells stimulated with LPA led to a marked reduction
(
85%) in oligodendrocyte survival (Fig. 6G,I–F; one-way
ANOVA; post hoc Bonferroni’s test, p 0.001; n	 4 per group),
suggesting that microglia become cytotoxic after LPA stimula-
tion., Oligodendrocyte cell death was reduced approximately
Figure 2. Intraspinal injection of LPA leads to microglia/macrophage activation. A, Quantification of microglia/macrophage immunoreactivity at 4 d after intraspinal injection of saline or LPA.
B–E, Representative images of spinal cords stained against Iba1 at the epicenter (B, D) and 1800m rostral to the injection site (C, E) of saline-injected (B, C) and LPA-injected (D, E) mice (n	 4
per group). *p	 0.006. Error bars indicate SEM. Scale bar, 250m.
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three times when microglia LPA1 was blocked with AM095 (Fig.
6G,I–F; one-way ANOVA; post hoc Bonferroni’s test, p 	 0.017;
n	 4 per group). Similar results were obtained from conditioned
mediumof LPA-stimulatedmicroglia cells isolated frommaLPA1
mice (Fig. 6H; two-way ANOVA; post hoc Bonferroni’s test, p
0.05; n	 4 per group). These data indicate that the activation of
LPA1 in microglial cells is responsible, in part, for the cytotoxic
effects mediated by LPA-stimulated microglia. Overall, our re-
sults suggest that demyelination triggered by intraspinal injection
of LPA is mediated, in part, by the activation of microglial LPA1,
with unclear participation of oligodendrocyte LPA signaling in
vivo.
LPA1 contributes to SCI pathophysiology
LPA–LPA1 signalingwas assessed for its role in secondary damage
and functional impairment after SCI in mice. Because maLPA1
null mice showed locomotor deficits (data not shown), probably
attributable to its developmental brain defects (Santin et al.,
2009), we used AM095 to assess the role of LPA1 in SCI. Oral
administration of AM095 significantly reduced locomotor im-
pairments based on the BMS assessment (Fig. 7A; p  0.001,
two-way RM-ANOVA; n	 8 per group). At the end of the follow
up (28 dpi), the BMS score was improved by 1.5 points after
AM095 treatment (Fig. 7A). Mice treated with saline showed oc-
casional plantar stepping and no coordination, whereas AM095
showed frequent/consistent plantar stepping and most of them
(87.5%) had coordination. In addition, the BMS subscore, which
Figure 3. Intraspinal injection of LPA leads to demyelination. A, Quantification of demyelination at 4 d after intraspinal injection of saline or LPA. B–E, Representative images of spinal cords
stainedwith LFB at the epicenter (B,D) and 1800mrostral to the injection site (C, E) in saline-injected (B, C) and LPA-injected (D, E)mice. F, High-magnification image of spinal cord tissue section
stained against NF (red) and fluoromyelin (green) showing the presence of NF structureswithin the demyelinating lesion at 4 d after intraspinal injection of LPA.G, Toluidine blue-stained section
from spinal cord at 4 d after intraspinal injection of LPA.H–J, Electronmicroscopy images taken from the demyelinating area showing fibers withmyelin breakdown (H, I ) and demyelinated axons
(J; see arrows; n	 4 per group). *p	 0.001. Error bars indicate SEM. Scale bar, 500m.
Figure 4. Expression of LPA1–LPA5 in the spinal cord parenchyma. Note that LPA1 is the
LPAR most highly expressed in the spinal cord. Data are presented as copies of receptor mRNA
relative to copies of GAPDHmRNA (n	 4 per time point). Error bars indicate SEM.
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assess fine aspects of locomotion, was markedly improved after
LPA1 blockade (Fig. 7B; p 0.001, two-way RM-ANOVA; n	 8
per group), whereas mice treated with AM095 were able to run at
significantly higher speeds on a treadmill (Fig. 7C; p 	 0.011,
Mantel–Cox test; n	 8 per group).
Electrophysiological tests designed to assess the preservation
of descending pathways of the spinal cord based onMEP analysis
were used on 28 dpi mice treated with AM095: treated animals
showed significantly greater MEP amplitudes for the GM com-
pared with controls (p	 0.018, t test; n	 8 per group), suggest-
ing an increase in spared functional descending tracts in the
spinal cord after the lesion (Fig. 7D,E). Mice administered
AM095were further assessed for amelioration of secondary tissue
damage. Histological sections of the spinal cord stained with
fluoromyelin revealed that animals treated with the LPA1 antag-
onist showed less demyelination at the injury epicenter and in
adjacent regions (Fig. 7F–H; p 0.001, two-way ANOVA; n	 8
per group). We also assessed whether the greater myelin sparing
observed after AM095 treatment was attributable to reduced ax-
onal loss or reduced demyelination. Spinal cord tissue section at
the injury epicenter, the most damaged area of the spinal cord,
revealed that AM095 did not enhance the number of NF fibers
but increased the percentage of axons labeled with MBP (Fig.
7I–K; p 	 0.034, t test; n 	 8 per group). However, AM095
treatment led to only minor improvement in neuronal sparing,
seen only at 400 m caudal to the injury epicenter (Fig. 7L–N).
These results suggest that the increased levels of LPA in the in-
jured spinal cord contributes to demyelination and loss of func-
tion by signaling via LPA1.
We finally assessed whether AM095 attenuated the inflamma-
tory response after SCI. FACS analysis of injured spinal cord
harvested at 7 dpi, whenmicroglial cell andmacrophages peak in
numbers after spinal cord contusion, revealed that AM095 did
not reduce microglia counts (Fig. 8). Similarly, AM095 did not
attenuate the infiltration of macrophages into the injured spinal
cord (Fig. 8). Overall, our data suggest that AM095 confers pro-
tection against demyelination by reducing the cytotoxic actions
of microglia LPA1 signaling but not its density.
Discussion
The results of the present study provide clear evidence that the
LPA–LPA1 pathway contributes to secondary damage after SCI.
LPA levels increase in the spinal cord after contusion injury, con-
tributing to activation ofmicroglia/macrophages and demyelina-
tion that are, in part, mediated by LPA1 signaling. Moreover, our
in vitro experiments suggest that detrimental actions of LPA1
involve signaling in microglial cells. Finally, we demonstrate that
selective inhibition of LPA1 after SCI confers protection from
demyelination and enhances locomotor skills. Overall, this work
demonstrates for the first time that the LPA–LPA1 pathway con-
tributes to secondary damage and is detrimental to functional
recovery after SCI.
Lysophospholipids, which include LPA and sphingosine
1-phosphate (S1P), have emerged as key modulators of inflam-
mation, including in nervous system disorders (Chun and Brink-
mann, 2011; David et al., 2012c; Choi and Chun, 2013). The
contribution of lysophospholipids to CNS pathology includes
experiments identifying lysolecithin (also known as lysophos-
phatidylcholine) as a potent demyelinating and inflammation-
inducing agent in the CNS (Ousman andDavid, 2000, 2001). S1P
has been demonstrated to play a key role in multiple sclerosis
(Brinkmann et al., 2010) through the actions of fingolimod
(FTY720; Chun and Brinkmann, 2011), a nonselective S1P re-
ceptor modulator, that was the first worldwide oral treatment
for relapsing forms of multiple sclerosis (Brinkmann et al.,
2010).
LPA is a lipid signaling molecule capable of evoking multiple
physiological responses in awide variety of cells (Choi et al., 2010;
Figure 5. LPA1 signalingmediates demyelination in the spinal cord. A, Quantification of the demyelinating injury in the spinal cord of animals injected with saline, LPA, or LPA1 plus AM095. B,
C, Representative images of spinal cords stained with LFB at the epicenter of the injection site in mice administered with LPA (B) or LPA plus AM095 (C). Note that demyelination was markedly
reduced in the absence of LPA1 activity. D, Quantification of the demyelinating injury after intraspinal injection of LPA in wild-type or maLPA1 null mice. E, F, Representative images of spinal cords
stainedwith LFB at the epicenter of the injection site inwild-type (E) andmaLPA1 null (F ) mice. Note that demyelinationwas reduced in the absence of LPA1 (n	 4 per group). Scale bar, 500m.
*p 0.05 saline versus LPA; *p 0.05 wild-type versus maLPA1 null mice. Error bars indicate SEM.
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Choi and Chun, 2013). LPA is present in low concentrations in
mammalian cells and tissues, but its concentrations in the blood
can range from 0.1 M in plasma to 10 M in serum. LPA is
synthesized in vivo from membrane phospholipids by multiple
pathways (Aoki et al., 2002; Choi et al., 2010; Choi and Chun,
2013). Here, we observed that LPA levels rise rapidly in the spinal
cord parenchyma after injury. This is likely attributable to a com-
bination of its de novo production in the contused spinal cord,
including through phospholipase A2 enzymes that are upregu-
lated in SCI (Titsworth et al., 2009; Lo´pez-Vales et al., 2011; Da-
vid et al., 2012c). However, plasma leakage and blood vessel
disruption, as well as serum production during the clotting pro-
cess, likely contribute to increases in LPA levels in SCI, as has
beenmodeled for post-hemorrhagic hydrocephaluswherein LPA
Figure 6. Microglia LPA1 mediates oligodendrocyte cell death. A, Effects of several concentrations of LPA on oligodendrocyte survival. B, Effects of LPA (1M) on OPC survival. C, Quantification
of oligodendrocyte cell death after stimulation with LPA or LPA plus AM095. D, Representative spinal cord sections from mice that received intraspinal injection of LPA showing that the
demyelinating lesion is associatedwith areas enriched inmicroglia. E, Representative FACS analysis ofmicroglia immunopannedwith the CD11b antibody fromadult CNS before and after being cell
sorted. F, Quantification of LPA1 expression in cultured and cell-sorted microglial cells. Note the microglia show similar levels of LPA1 in both conditions. G, Assessment of conditioned medium of
unstimulated (control) microglia or conditioned medium of microglia stimulated with LPA or LPA plus AM095 on oligodendrocyte survival.H, Assessment of conditioned medium of unstimulated
(DMSO; control) or LPA-stimulated microglial cells harvested from wild-type or LPA1 null mice. I, K, Representative images of oligodendrocytes (MBP
) from cultures treated with conditioned
medium from untreated microglia (DMSO; control) or microglia treated with LPA or LPA plus AM095 stimulated microglia. Note that gene deletion of pharmacological blockade of microglia LPA1
significantly reduces oligodendrocyte cell death. Scale bar, 100m. *p 0.05 versus control; #p 0.05 versus LPA or LPA wild type). Error bars indicate SEM (n	 4 per group).
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Figure 7. LPA1 blockade enhances functional outcomes and reduces demyelination after SCI. A, B, Animals treated with AM095 show significant improvement in locomotor performance
compared with saline-treated mice using the nine-point BMS (A) and the 11-point BMS subscore (B), as well as faster locomotion on a treadmill (C). D, E, Mice treated with AM095 show greater
preservation of MEPs. D, Quantification of MEP recordings from GM at 28 d after SCI. E, Representative MEP recordings frommice treated with saline or AM095. F, Quantification of myelin sparing
at various distances rostral and caudal to the injury epicenter revels significant reduction in tissue loss in mice treated with AM095 at the epicenter of the injury and in adjacent sections. G, H,
Representativemicrographs showingmyelin sparing at the injury epicenter in section stained against fluoromyelin frommice treatedwith saline (G) or AM095 (H; n	 8 per group). Scale bar, 500
m. *p 0.05. I, Quantification of axon andmyelin sparing in the dorsal column at the epicenter of the injury. Treatment with AM095 resulted in greater myelin but not axonal preservation. J, K,
Representative micrographs of the dorsal columns stained against NF and MBP from mice treated with saline (J ) and AM095 (K ). L, Quantification of ventral (Figure legend continues.)
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is an active factor in hemorrhagic fluids (Yung et al., 2011). In-
deed, the presence of the 20:4 LPA in the injured spinal cord,
which is a major form of LPA in plasma (Scherer et al., 2009) but
that was not found in the intact cord, supports hemorrhagic
blood fractions as a source of LPA in SCI.
Exogenous LPA can initiate a large range of neural sequelae
within the nervous system that includes effects onmost cell types
and activities in disease models. Cell types include developing
neural cells (Dubin et al., 1999, 2010; Kingsbury et al., 2003),
astrocytes (Shano et al., 2008; Spohr et al., 2008), microglia
(Mo¨ller et al., 2001; Ma et al., 2013), oligodendrocytes and
Schwann cells (Weiner et al., 1998, 2001), and neurons (Fuku-
shima et al., 2002; Trimbuch et al., 2009; Lin et al., 2012). Disease
models include pain (Inoue et al., 2004; Lin et al., 2012; Ma et
al., 2013), hypoxia and ischemia (Herr et al., 2011; Halder et al.,
2013), demyelination (Inoue et al., 2004, 2008a,b; Nagai et al.,
2010), and behavioral disorders (Contos et al., 2000, 2002; Santin
et al., 2009; Castilla-Ortega et al., 2012; Pedraza et al., 2014).
These physiological responses linked to LPA activation are trig-
gered by a variety of downstream pathways, including Ca2mo-
bilization, adenylyl cyclase inhibition, activation of Rho,
mitogen-activated protein kinase, phospholipase C, and Akt
(Yung et al., 2014, 2015; Sheng et al., 2015). The findings here
identify LPA as a new trigger of secondary damage in SCI. The
mechanism involves LPA1, which is the mostly highly expressed
LPAR in the spinal cord, suggesting that the detrimental actions
of LPA are likely to bemediated by binding to LPA1. ThemaLPA1
knock-out mice and mice treated with AM095, a selective LPA1
inhibitor (Swaney et al., 2011), showed reducedmyelin loss when
LPA is injected into the intact spinal cord, revealing that LPA1
signaling is involved in the LPA-demyelinating lesion, consistent
with previous studies within the peripheral nervous system (In-
oue et al., 2004, 2008a,b; Xie et al., 2008; Nagai et al., 2010;Halder
et al., 2013). SCI effects appear to involve microglia/macro-
phages. Although we also noticed mild astrogliosis in the spinal
cord after LPA injection, the effects of the LPA were more pro-
nounced in microglia/macrophages, suggesting that they are
more susceptible to activation by LPA. Importantly, we also ob-
served that intraspinal injection of LPA led to the development of
a demyelinating lesion in the spinal cord. This is of crucial im-
portance because myelin loss contributes to functional impair-
ments after SCI and in other neural conditions, such as multiple
sclerosis.
LPA1 is found on oligodendrocytes (Weiner et al., 1998), and
its expression appears shortly before maturation/myelination
(Garcia-Diaz et al., 2014). Although LPA1 signaling plays a key
role in the regulation of oligodendrocyte differentiation andmy-
elination in the CNS (Garcia-Diaz et al., 2014), little is known
about the effects of LPA on mature oligodendrocytes. Our data
indicate that LPA exerts mild toxicity in oligodendrocytes at
doses 1 M but not in oligodendrocyte precursor cells. The
mechanismunderlying LPA toxicity is unknown, but this effect is
notmediated via LPA1 because AM095 failed to rescue cell death,
at least in cell culture. Hence, LPA-mediated demyelination is
likely to be mediated by the activation of LPA1 in other cell types
rather than to direct activation of LPA1 in oligodendrocytes, con-
sistent with our data showing that intraspinal injection of LPA
leads to activation of microglia/macrophages that express LPA1
in vivo and in vitro, as we and other authors have demonstrated
(Tham et al., 2003). Conditioned medium of microglia stimu-
lated with LPA mediates marked oligodendrocyte cell death, in-
dicating that microglial become cytotoxic during LPA
stimulation of LPA1 signaling. Interestingly, selective blockade or
gene deletion of LPA1 in LPA-stimulated microglial cells appears
to increase oligodendrocyte cell survival. This result suggests that
microglia LPA1 is involved in the development of the demyelinat-
ing injury triggered by LPA injection into the spinal cord. How-
ever, LPA1 inhibition did not completely suppress the harmful
effects of LPA-stimulatedmicroglia, suggesting that othermicro-
glial LPARs may contribute to oligodendrocyte cell death. Simi-
larly, myelin loss was not completely abrogated in the maLPA1
null mice or in mice administered AM095, indicating that other
LPARs or other non-LPA-mediated mechanisms also contribute
to demyelination. However, LPA1 blockade does not reduce mi-
croglia or macrophage accumulation in SCI, but it likely attenu-
ates the harmful effects linked to LPA1 activation. The soluble
factors released by microglial cells during LPA1 activation that
mediate oligodendrocyte cell death are unidentified yet, but it can
be attributed to cytokine and free radical production because
LPA regulates the production of these factor in several conditions
(Cummings et al., 2004; Fang et al., 2004; Sevastou et al., 2013).
Activation of Rho, which can be induced by LPA, is one of the
most important intracellular pathways that inhibit axonal regen-
4
(Figure legend continued.) horn neuron survival at various distances rostral and caudal to the
injury epicenter reveals significantly greater neuronal survival in mice treated with AM095.M,
N, Representative micrographs showing sparing of ventral horn neurons in mice administered
with saline (M) and AM095 (N) in sections stained against NeuN at 600m rostral to the injury
epicenter. Error bars indicate SEM. n	 8 per group.
Figure 8. AM095 does not attenuate inflammatory response. A, B, Representative density plots of FACS analysis showingmicroglia andmyeloid cells in the injured spinal cord of saline-treated
(A) or AM095-treated (B)mice at 7 dpi.Myeloid cell were further discriminated inmacrophages based on F4/80 expression. C, Graph showingmicroglia andmacrophage counts in the injured spinal
cord after LPA1 blockade. Note that treatment with AM095 did not reduce the numbers of microglia and macrophages. Error bars indicate SEM. n	 4 per group.
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eration. Previous works revealed that LPA triggers axonal col-
lapse and retraction (Tigyi et al., 1996; Birgbauer and Chun,
2006), in part by activating Rho (Fincher et al., 2014). However,
the inhibitory effects of LPA on axonal growth are not triggered
by LPA1, at least in vitro (Birgbauer and Chun, 2010).
Reports that a “B3” antibody that can bind to LPA and other
lysophospholipids and mediates protection after spinal cord he-
misection and traumatic brain injury (Goldshmit et al., 2012;
Crack et al., 2014) are consistent with increased LPA in CNS
injuries. However, mechanistic validation, including demonstra-
tion that B3 specifically lowers pathogenic LPA availability to
account for its effects, remain to be established. Nevertheless,
possible therapies targeting LPA, its biosynthetic enzymes,
and/or its receptorsmay represent viable strategies for improving
clinical outcomes for SCI in the future. In particular, our results
suggest that LPA1 could be a novel therapeutic target for the
treatment of acute SCI, as well as other CNS conditions in which
demyelination contributes to the pathology.
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